| ALPAX | FFFMX | ALPAX / FFFMX | |
| Total Expense Ratio | 1.09 | 0.32 | 341% |
| Annual Report Gross Expense Ratio | 1.09 | 0.32 | 341% |
| Fund Existence | 25 years | 5 years | - |
| Gain YTD | 13.879 | 15.674 | 89% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 2500 | 250 | 1,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.67B | 112B | 2% |
| Annual Yield % from dividends | 1.33 | 1.72 | 77% |
| Returns for 1 year | 1.92 | 7.33 | 26% |
| Returns for 3 years | 18.06 | 32.98 | 55% |
| Returns for 5 years | 13.93 | 59.69 | 23% |
| Returns for 10 years | 54.07 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| KCEIX | 12.56 | 0.06 | +0.48% |
| Knights of Columbus Long/Short Eq I | |||
| AEUDX | 9.07 | 0.04 | +0.44% |
| American Century Equity Income R6 | |||
| LEAIX | 15.92 | 0.04 | +0.25% |
| Lazard Emerging Markets Eq Advtg Instl | |||
| FBTCX | 28.38 | N/A | N/A |
| Fidelity Advisor Biotechnology C | |||
| ALCBX | 13.41 | N/A | N/A |
| ALPS/Smith Balanced Opportunity C | |||